Abstract

BackgroundModern rheumatoid arthritis (RA) care is based on early DMARD initiation, tight control and treat-to-target strategies aiming for abrogation of inflammation to optimize long term outcomes. However, even in the...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Predictors of sustained remission in patients with early rheumatoid arthritis treated according to an aggressive treat-to-target protocol.
... Espen A Haavardsholm
Rheumatology (Oxford, England) | VOL. 57
, et. al. ... Espen A Haavardsholm
26 Jul 2018
FRI0075 A multi-biomarker disease activity (vectra™ da algorithm) score and components are associated with sustained clinical remission in rheumatoid arthrits: the remira study.
G H Kingsley ... N Defranoux
Annals of the Rheumatic Diseases | VOL. 72
G H Kingsley, et. al.G H Kingsley ... N Defranoux
01 Jun 2013
THU0111 Frequency and predictors of sustained remission in patients with early rheumatoid arthritis treated with conventional synthetic disease modifying drugs
G Sakellariou ... F Benaglio
Annals of the Rheumatic Diseases | VOL. 77
G Sakellariou, et. al.G Sakellariou ... F Benaglio
01 Jun 2018
FRI0127 Treatment Targets with First Line Biological Agents in Early and Longstanding Rheumatoid Arthritis Patients
I Duca ... M Barba
Annals of the Rheumatic Diseases | VOL. 74
I Duca, et. al.I Duca ... M Barba
01 Jun 2015
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers